Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissue

Vollbrecht, Claudia; Hoffmann, Inga; Lehmann, Annika; Merkelbach-Bruse, Sabine; Fassunke, Jana; Wagener-Ryczek, Svenja; Ball, Markus; Dimitrova, Lora; Hartmann, Arndt; Stohr, Robert; Erber, Ramona; Weichert, Wilko; Pfarr, Nicole; Bohlmann, Lisa; Jung, Andreas; Dietmaier, Wolfgang; Dietel, Manfred; Horst, David und Hummel, Michael (2022): Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissue. In: Virchows Archiv, Bd. 482, Nr. 4: S. 697-706

Abstract

Precision oncology based on specific molecular alterations requires precise and reliable detection of therapeutic targets in order to initiate the optimal treatment. In many European countries-including Germany-assays employed for this purpose are highly diverse and not prescribed by authorities, making inter-laboratory comparison difficult. To ensure reproducible molecular diagnostic results across many laboratories and different assays, ring trials are essential and a well-established tool. Here, we describe the design and results of the ring trial for the detection of therapeutically relevant PIK3CA hotspot mutations in HR+/HER2-breast cancer tissue and liquid biopsy (LB). For PIK3CA mutation detection in tissue samples, 43 of the 54 participants (80%) provided results compliant with the reference values. Participants using NGS-based assays showed higher success rate (82%) than those employing Sanger sequencing (57%). LB testing was performed with two reference materials differing in the length of the mutated DNA fragments. Most participants used NGS-based or commercial realtime PCR assays (70%). The 167 bp fragments led to a successful PIK3CA mutation detection by only 31% of participants whereas longer fragments of 490 bp were detectable even by non-optimal assays (83%). In conclusion, the first ring trial for PIK3CA mutation detection in Germany showed that PIK3CA mutation analysis is broadly established for tissue samples and that NGS-based tests seem to be more suitable than Sanger sequencing. PIK3CA mutation detection in LB should be carried out with assays specifically designed for this purpose in order to avoid false-negative results.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 0945-6317
• Sprache: Englisch